CorMedix IncNASDAQ:CRMD
- LAST PRICE8.2550
- TODAY'S CHANGE (%)0.0250 (0.3038%)
- Bid / Lots8.2500/ 1
- Ask / Lots8.2600/ 2
- Open / Previous Close8.3400 / 8.2300
- Day Range
- 52 Week Range
- Volume208,301
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 27077 | 8.345 |
| 09:34 ET | 5042 | 8.3181 |
| 09:36 ET | 2474 | 8.25 |
| 09:38 ET | 2856 | 8.28 |
| 09:39 ET | 5313 | 8.245 |
| 09:41 ET | 6745 | 8.254156 |
| 09:43 ET | 4192 | 8.23 |
| 09:45 ET | 4037 | 8.25 |
| 09:48 ET | 4753 | 8.31 |
| 09:50 ET | 27000 | 8.17 |
| 09:52 ET | 2480 | 8.1514 |
| 09:54 ET | 5379 | 8.1302 |
| 09:56 ET | 6856 | 8.072185 |
| 09:57 ET | 367 | 8.0811 |
| 09:59 ET | 100 | 8.08 |
| 10:01 ET | 11012 | 8.1 |
| 10:03 ET | 1900 | 8.13 |
| 10:06 ET | 4900 | 8.14 |
| 10:08 ET | 8952 | 8.17 |
| 10:10 ET | 600 | 8.16 |
| 10:12 ET | 1945 | 8.165 |
| 10:14 ET | 4801 | 8.165 |
| 10:15 ET | 18718 | 8.175 |
| 10:17 ET | 500 | 8.16 |
| 10:19 ET | 3151 | 8.1503 |
| 10:21 ET | 100 | 8.165 |
| 10:24 ET | 800 | 8.2299 |
| 10:26 ET | 100 | 8.22 |
| 10:28 ET | 200 | 8.21 |
| 10:30 ET | 645 | 8.23 |
| 10:32 ET | 200 | 8.22 |
| 10:33 ET | 450 | 8.2104 |
| 10:35 ET | 300 | 8.19 |
| 10:37 ET | 200 | 8.1858 |
| 10:39 ET | 700 | 8.19 |
| 10:42 ET | 400 | 8.18 |
| 10:46 ET | 500 | 8.19 |
| 10:48 ET | 770 | 8.24 |
| 10:50 ET | 1050 | 8.24 |
| 10:51 ET | 1015 | 8.23 |
| 10:53 ET | 1100 | 8.24 |
| 10:55 ET | 100 | 8.24 |
| 10:57 ET | 814 | 8.24 |
| 11:00 ET | 500 | 8.265 |
| 11:06 ET | 300 | 8.24 |
| 11:08 ET | 200 | 8.245 |
| 11:09 ET | 2559 | 8.255 |
| 11:11 ET | 1022 | 8.25 |
| 11:13 ET | 1049 | 8.2498 |
| 11:15 ET | 1964 | 8.235 |
| 11:18 ET | 1400 | 8.25 |
| 11:20 ET | 314 | 8.25 |
| 11:22 ET | 500 | 8.22 |
| 11:24 ET | 133 | 8.21 |
| 11:26 ET | 2306 | 8.25 |
| 11:27 ET | 2200 | 8.25 |
| 11:29 ET | 1000 | 8.255 |
| 11:33 ET | 100 | 8.255 |
Sep 19, 2024
CorMedix Inc. Announces New Commercial Agreement, from 8:00AM ET on Thursday Sep 19, 2024 by Dow Jones
8:00AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 13, 2024
CorMedix Inc. to Present at the Cantor Global Healthcare Conference, from 8:30AM ET on Friday Sep 13, 2024 by Dow Jones
8:30AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 9, 2024
CorMedix Inc. Announces New Commercial Agreement, from 10:52AM ET on Monday Sep 09, 2024 by Dow Jones
10:52AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 459.7M | -8.9x | --- |
Zevra Therapeutics Inc | 384.6M | -4.1x | --- |
Cipla Ltd | 15.7B | 0.0x | --- |
Elite Pharmaceuticals Inc | 415.5M | 20.3x | --- |
Calliditas Therapeutics AB | 1.2B | -22.6x | --- |
Incannex Healthcare Inc | 32.4M | 0.0x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Head of Clinical and Medical Affairs
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Commercial Officer
- Erin Mistry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $459.7M |
|---|---|
Revenue (TTM) | $806.1K |
Shares Outstanding | 55.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.60 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | 570.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,212.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
